Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29622995 | 1.00 | F2R (0.40) | F2RMAPTPOLBTSHRKMT2A | |
| SCHEMBL21857985 | 0.86 | F2R (0.41) | F2RMAPTPOLBTSHRKMT2A | |
| SCHEMBL21767653 | 0.80 | F2R (0.40) | F2RMAPTPOLBTSHRKMT2A | |
| SCHEMBL31072018 | 0.80 | F2R (0.40) | F2RMAPTPOLBTSHRKMT2A | |
| SCHEMBL5777608 | 0.79 | TSHR (0.55) | F2RMAPTPOLBTSHRKMT2A | |
| SCHEMBL25757435 | 0.79 | F2R (0.39) | F2RMAPTKMT2APKMSMN1; SMN2 | |
| SCHEMBL21858009 | 0.78 | MAPT (0.42) | MAPTPOLBTSHRKMT2AMEN1 | |
| SCHEMBL29622873 | 0.78 | MAPT (0.42) | MAPTPOLBTSHRKMT2AMEN1 | |
| SCHEMBL21857999 | 0.76 | F2R (0.41) | F2RMAPTPOLBTSHRKMT2A | |
| SCHEMBL21857875 | 0.76 | FBP1 (0.39) | MAPTPOLBTSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340508-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12435034-B2 | Process of preparing 3-fluoro-5(((1R,2AR)-3,3,4,4-tetrafluoro-1,2A-dihydroxy-2,2A,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile | NIKANG THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-12391642-B2 | Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12077506-B2 | Indane derivatives as hypoxia inducible factor-2(α) inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20230373909-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373909-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373909-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11753366-B2 | Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753366-B2 | Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753366-B2 | Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2021212062-A1 | HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASES | NIKANG THERAPEUTICS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20210246102-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-08-12 | — | — | US | disclosed |
| US-20210246102-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-08-12 | — | — | US | disclosed |
| WO-2021016280-A1 | TRICYCLIC DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021016280-A1 | TRICYCLIC DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| US-20200361855-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| WO-2020214853-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020214853-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020081695-A1 | INDANE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020081695-A1 | INDANE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753366-B2 | Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors | HIF1AN, HIF1A, HYOU1 | F2R 2751/4885MAPT 4166/4885POLB 2793/4885 |
| US-20210246102-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | HIF1AN, HIF1A, HYOU1 | F2R 2751/4885MAPT 4166/4885POLB 2793/4885 |
| US-12077506-B2 | Indane derivatives as hypoxia inducible factor-2(α) inhibitors | HIF1AN, HIF1A, NFE2L2 | F2R 2134/4885MAPT 3270/4885POLB 1663/4885 |
| US-20250340508-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | HIF1AN, HIF1A, HYOU1 | F2R 2751/4885MAPT 4166/4885POLB 2793/4885 |
| US-12391642-B2 | Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors | HIF1AN, HIF1A, HYOU1 | F2R 2751/4885MAPT 4166/4885POLB 2793/4885 |
| US-12435034-B2 | Process of preparing 3-fluoro-5(((1R,2AR)-3,3,4,4-tetrafluoro-1,2A-dihydroxy-2,2A,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile | CYP4B1, CYP1B1, CYP3A4 | F2R 739/4885MAPT 2530/4885POLB 3175/4885 |
| US-20230373909-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | HIF1AN, HIF1A, HYOU1 | F2R 2751/4885MAPT 4166/4885POLB 2793/4885 |
| US-20200361855-A1 | TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | HIF1AN, HIF1A, HYOU1 | F2R 2751/4885MAPT 4166/4885POLB 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.